Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men
Objective: HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM. Methods: The Study of the Prevention of Anal Cancer (SPANC) is a...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-06-01
|
| Series: | Papillomavirus Research |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405852116300647 |
| _version_ | 1818265356931694592 |
|---|---|
| author | I. Mary Poynten Sepehr N. Tabrizi Fengyi Jin David J. Templeton Dorothy A. Machalek Alyssa Cornall Samuel Phillips Christopher K. Fairley Suzanne M. Garland Carmella Law Andrew Carr Richard J. Hillman Andrew E. Grulich |
| author_facet | I. Mary Poynten Sepehr N. Tabrizi Fengyi Jin David J. Templeton Dorothy A. Machalek Alyssa Cornall Samuel Phillips Christopher K. Fairley Suzanne M. Garland Carmella Law Andrew Carr Richard J. Hillman Andrew E. Grulich |
| author_sort | I. Mary Poynten |
| collection | DOAJ |
| description | Objective: HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM. Methods: The Study of the Prevention of Anal Cancer (SPANC) is an ongoing, prospective cohort study of HIV-positive and HIV-negative Australian GBM. Participants completed questionnaires and underwent an anal swab for HPV genotyping using Roche Linear Array. We analysed baseline data from SPANC by HPV type, mean number of types, stratified by age and HIV status. Results: Anal HPV results from 606 (98.2%) of 617 participants (median age 49 years, 35.7% HIV-positive) showed 525 (86.7%) had â¥1 HPV type and 178 (29.4%) had HPV16. Over one third of participants (214, 35.3%) had no nonavalent vaccine-preventable types detected. Two (0.3%) participants had all quadrivalent types and none had all nonavalent vaccine types. HIV-positive participants (p<0.001) and younger participants (p=0.059) were more likely to have more vaccine-preventable HPV types detected. Conclusion: Anal HPV was highly prevalent in this largely community-based GBM cohort. Vaccine-preventable HPV16 was detected in approximately one third of participants. These findings suggest that the potential efficacy of HPV vaccination of older GBM should be explored. Keywords: Human papillomavirus, HPV, Anal, Vaccine, Prevalence, Gay and bisexual men, MSM, HIV |
| first_indexed | 2024-12-12T19:49:31Z |
| format | Article |
| id | doaj.art-6f6a192821204cf793aaaf684fc8cfb9 |
| institution | Directory Open Access Journal |
| issn | 2405-8521 |
| language | English |
| last_indexed | 2024-12-12T19:49:31Z |
| publishDate | 2017-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Papillomavirus Research |
| spelling | doaj.art-6f6a192821204cf793aaaf684fc8cfb92022-12-22T00:14:00ZengElsevierPapillomavirus Research2405-85212017-06-0138084Vaccine-preventable anal human papillomavirus in Australian gay and bisexual menI. Mary Poynten0Sepehr N. Tabrizi1Fengyi Jin2David J. Templeton3Dorothy A. Machalek4Alyssa Cornall5Samuel Phillips6Christopher K. Fairley7Suzanne M. Garland8Carmella Law9Andrew Carr10Richard J. Hillman11Andrew E. Grulich12The Kirby Institute, University of New South Wales, Sydney, Australia; Corresponding author.Regional HPV LabNet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Womenâs Hospital, Parkville, Victoria, Australia; Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia; Murdoch Childrenâs Research Institute, Parkville, Victoria, AustraliaDepartment of Obstetrics and Gynecology, University of Melbourne, Victoria, AustraliaRPA Sexual Health and Central Clinical School, University of Sydney, Sydney, AustraliaRegional HPV LabNet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Womenâs Hospital, Parkville, Victoria, Australia; Murdoch Childrenâs Research Institute, Parkville, Victoria, AustraliaRegional HPV LabNet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Womenâs Hospital, Parkville, Victoria, Australia; Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia; Murdoch Childrenâs Research Institute, Parkville, Victoria, AustraliaRegional HPV LabNet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Womenâs Hospital, Parkville, Victoria, Australia; Murdoch Childrenâs Research Institute, Parkville, Victoria, AustraliaMelbourne Sexual Health Centre, Alfred Health, Carlton, Melbourne, Victoria, Australia; Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, AustraliaDepartment of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia; Murdoch Childrenâs Research Institute, Parkville, Victoria, Australia; Department of Microbiology and Infectious Diseases, Royal Women's Hospital, Parkville, Melbourne, Victoria, AustraliaSt Vincentâs Hospital, Sydney, AustraliaSt Vincentâs Hospital, Sydney, AustraliaSt Vincentâs Hospital, Sydney, Australia; Western Sydney Sexual Health Centre, University of Sydney, Sydney, AustraliaThe Kirby Institute, University of New South Wales, Sydney, AustraliaObjective: HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM. Methods: The Study of the Prevention of Anal Cancer (SPANC) is an ongoing, prospective cohort study of HIV-positive and HIV-negative Australian GBM. Participants completed questionnaires and underwent an anal swab for HPV genotyping using Roche Linear Array. We analysed baseline data from SPANC by HPV type, mean number of types, stratified by age and HIV status. Results: Anal HPV results from 606 (98.2%) of 617 participants (median age 49 years, 35.7% HIV-positive) showed 525 (86.7%) had â¥1 HPV type and 178 (29.4%) had HPV16. Over one third of participants (214, 35.3%) had no nonavalent vaccine-preventable types detected. Two (0.3%) participants had all quadrivalent types and none had all nonavalent vaccine types. HIV-positive participants (p<0.001) and younger participants (p=0.059) were more likely to have more vaccine-preventable HPV types detected. Conclusion: Anal HPV was highly prevalent in this largely community-based GBM cohort. Vaccine-preventable HPV16 was detected in approximately one third of participants. These findings suggest that the potential efficacy of HPV vaccination of older GBM should be explored. Keywords: Human papillomavirus, HPV, Anal, Vaccine, Prevalence, Gay and bisexual men, MSM, HIVhttp://www.sciencedirect.com/science/article/pii/S2405852116300647 |
| spellingShingle | I. Mary Poynten Sepehr N. Tabrizi Fengyi Jin David J. Templeton Dorothy A. Machalek Alyssa Cornall Samuel Phillips Christopher K. Fairley Suzanne M. Garland Carmella Law Andrew Carr Richard J. Hillman Andrew E. Grulich Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men Papillomavirus Research |
| title | Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men |
| title_full | Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men |
| title_fullStr | Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men |
| title_full_unstemmed | Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men |
| title_short | Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men |
| title_sort | vaccine preventable anal human papillomavirus in australian gay and bisexual men |
| url | http://www.sciencedirect.com/science/article/pii/S2405852116300647 |
| work_keys_str_mv | AT imarypoynten vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT sepehrntabrizi vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT fengyijin vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT davidjtempleton vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT dorothyamachalek vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT alyssacornall vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT samuelphillips vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT christopherkfairley vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT suzannemgarland vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT carmellalaw vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT andrewcarr vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT richardjhillman vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen AT andrewegrulich vaccinepreventableanalhumanpapillomavirusinaustraliangayandbisexualmen |